J.D. Wofford
Cardinal Glennon Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.D. Wofford.
Transfusion | 2010
Donna Regan; J.D. Wofford; Donna A. Wall
BACKGROUND: Umbilical cord blood (UCB) products have traditionally been thawed using a washing method intended to stabilize the cells, reduce dimethyl sulfoxide (DMSO) toxicity, and remove potentially ABO‐incompatible red blood cell (RBC) stroma and plasma. Concerns with this approach include loss of total nucleated cells (TNCs), bag breakage during centrifugation, and poor reproducibility by transplant centers unfamiliar with this technique. We rationalized that a simple 1:1 dilution without centrifugation would stabilize the product and reduce the DMSO concentration by 50%, allowing for a controlled thaw in the laboratory without the risks of cell loss.
Transfusion | 2010
Michael Solomon; J.D. Wofford; Cory Johnson; Donna Regan; Michael H. Creer
BACKGROUND: Cord blood (CB) viability determines product quality and varies with time and temperature of exposure before cryopreservation. Global viability assessment may not reflect viability of white blood cell (WBC) subsets, CD34+ cell viability, or hematopoietic stem/progenitor cells function.
Journal of Pediatric Hematology Oncology | 2009
John Puetz; Ginger Darling; Kimberly A. McCormick; J.D. Wofford
Background Little recent data are available describing fresh frozen plasma (FFP) use in neonates. The purpose of this study was to determine the outcomes of FFP transfusions in neonates. Patients and Methods A single institution, observational, and retrospective review of each transfusion of FFP given to neonates admitted to a neonatal intensive care unit over a 2-year period. Results One hundred and seventy-three neonates were identified as having received FFP, giving a prevalence of FFP use at 12%. By far the most common determining factor for FFP use was an association with an abnormal activated partial thromboplastin time or prothrombin time (52%). Other factors included bleeding, invasive procedures, volume expansion, necrotizing enterocolitis, cardiopulmonary bypass, and hydrops fetalis. Of objectively accessible responses, FFP was able to correct abnormal coagulation tests into the normal range only 40% of the time. Twenty-four neonates received recombinant factor VIIa (rFVIIa) after first receiving FFP. The prevalence of thrombotic events was not higher in neonates receiving rFVIIa than those receiving FFP alone. Conclusions FFP was widely used in this neonatal unit. As data showing the predictive value of coagulation tests in neonates are discrepant, it is unclear if FFP was being appropriately used. Prospective, controlled data are required.
Cytotherapy | 2007
J.D. Wofford; J. Kemp; Donna Regan; Michael H. Creer
BACKGROUND For ethnic minority patients where a suitably matched BM or peripheral blood donor is frequently unavailable, cord blood offers an opportunity for hematopoietic stem cell transplantation. Focused recruitment of ethnic minorities for cord blood donation has been proposed as the preferred strategy to improve access for minority recipients to cord blood for transplantation. The aim of this study was to evaluate cord blood characteristics for Caucasian and African American donors and the success of ethnically mismatched UC blood transplantation in African American recipients. METHODS Retrospective data analysis was performed comparing the characteristics of 556 cord blood units from African American and Caucasian donors. The outcomes of 18 African American ethnically mismatched transplant recipients were compared with a paired sample of 18 ethnically matched Caucasian recipients. RESULTS The fraction of collected units meeting acceptability criteria from African Americans was significantly lower compared with Caucasians (P = <0.0001). Additionally, African Americans had a significantly lower post-processing total nucleated cell count (TNC) compared with Caucasians (P=0.007) but there were no other significant differences in conventionally measured product characteristics. In the transplant analysis, there was no difference in overall survival at 1 year (P=0.85) or time to neutrophil engraftment (P=0.92) between the two patient populations. DISCUSSION At comparable levels of TNC dose and HLA matching, the use of ethnically mismatched UC blood units as a source for allogeneic unrelated transplant can result in successful transplant outcomes for African American patients.
Biology of Blood and Marrow Transplantation | 2005
J.D. Wofford; Donna Regan; Michael H. Creer
Biology of Blood and Marrow Transplantation | 2006
Donna Regan; L.M. Grunzinger Nelms; J.D. Wofford; J.M.F. Alonso; Michael H. Creer
Biology of Blood and Marrow Transplantation | 2011
Deepika Bhatla; J.D. Wofford; Donna Regan
Biology of Blood and Marrow Transplantation | 2010
J.D. Wofford; Donna Regan; J.M. Sander; D. Bhatla
Biology of Blood and Marrow Transplantation | 2009
B.M. Triplett; J.D. Wofford; K. Mueckl; Donna Regan; V. Geiler
Biology of Blood and Marrow Transplantation | 2008
B.M. Triplett; Donna Regan; J.D. Wofford; J. Schaeffler; William Ferguson